This Healthcare Stock Is Down 40%, But the Growth Story Isn’t Dead
TransMedics (NASDAQ:TMDX) faces a serious margin test after a rough stock decline, but revenue growth remains strong. The central question is whether heavy infrastructure spending is a temporary drag, or a warning sign that the business is becoming harder to scale profitably. Stock prices used were the market prices of May 25, 2026. The video … Read more
